Drug Therapy for Rheumatoid Arthritis in Adults
Comparative Adverse Effects of Combining DMARDs
Combining methotrexate (MTX) or other oral disease-modifying anti-rheumatic drugs (DMARDs) with a biologic DMARD does not alter the adverse event rate found with the biologic DMARD alone. The strength of evidence for this finding is low.
Combining MTX and biologic DMARDs demonstrates a better tolerability profile than MTX alone. The strength of evidence for this finding is low.
Evidence is insufficient to estimate differences in rates of specific adverse events between the biologic and oral DMARDs.
Keywords: rheumatoid arthritis | RA | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic DMARD | withdrawal | adverse events | tolerability | methotrexate | adverse effects
- Donahue KE, Jonas D, Hansen RA, et al. Drug Therapy for Rheumatoid Arthritis in Adults: An Update. Comparative Effectiveness Review No. 55 (Prepared by the RTI International–University of North Carolina Evidence-based Practice Center under Contract No. 290-2007-10056-I). Rockville, MD: Agency for Healthcare Research and Quality; April 2012. AHRQ Publication No. 12-EHC025-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsra.cfm.
Your slide tray is being processed.